BMP AI Technologies Inc. has issued a statement regarding the Caveat Emptor designation applied by OTC Markets Group on October 22, 2025. The designation, which translates to "buyer beware" in Latin, represents a significant regulatory action that alerts investors to potential concerns about a company's public disclosures or market activity.
The Company has been in active communication with OTC Markets to understand the basis for the designation. OTC Markets has indicated that the designation relates to its review of the Company's publicly available financial information and the recent market activity in its securities. This development highlights the regulatory scrutiny that companies face when trading on over-the-counter markets, where disclosure requirements differ from major exchanges.
OTC Markets has provided the Company with a detailed list of supplemental information that it has requested from the Company. The Company intends to furnish all such information promptly and expects to complete its response within the week. This rapid response demonstrates the Company's commitment to regulatory compliance and transparency in its operations.
The Company reiterates that it has not authorized or engaged any third parties to conduct promotional, marketing, or investor relations campaigns on its behalf. This statement addresses potential concerns about artificial market activity or improper promotion that could have triggered regulatory attention. The Company remains fully committed to transparency, regulatory compliance, and accurate disclosure, and is cooperating fully with OTC Markets to expedite the removal of the caveat emptor designation.
OTC Markets has informed the Company that such designations are generally maintained for a 30 day period; however, under the circumstances, the Company and its legal counsel will be requesting that the 30-day policy be waived and that the designation be removed upon verification of the requested supplemental information. This potential acceleration of the resolution process could benefit both the Company and its shareholders by minimizing market uncertainty.
We are aware of the designation and are taking this matter very seriously, said a spokesperson for BMPA. Our team is fully committed to cooperating with OTC Markets and ensuring our compliance. We will continue to keep our shareholders informed as we work through this process.
The Company confirms that its operations and SEC filings remain current. Additional information about BMP AI Technologies Inc. is available at https://www.bmpaitech.com or by visiting https://www.sec.gov. The situation underscores the importance of regulatory oversight in maintaining market integrity and protecting investors from potential misinformation or inadequate disclosure.
This regulatory action serves as a reminder to investors about the risks associated with over-the-counter trading, where companies may face different disclosure standards than those listed on major exchanges. The outcome of BMP AI Technologies' response to OTC Markets could set precedents for how similar cases are handled in the future, potentially influencing regulatory approaches to emerging technology companies operating in artificial intelligence and blockchain sectors.
